ObsEva : to Participate in JP Morgan Healthcare Conference January 7-10, 2019

Press Release in Pdf

Geneva, Switzerland and Boston - January 2, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that Company Management will be participating in the JP Morgan Healthcare Conference taking place January 7-10, 2019 in San Francisco. ObsEva will present on Tuesday, January 8, 2019 at 4 p.m. Pacific Time (PT).

The presentation webcast will be available in the 'Investors' section of ObsEva's website www.ObsEva.com.

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol 'OBSV' and on the SIX Swiss Exchange where it is trading under the ticker symbol 'OBSN'. For more information, please visit www.ObsEva.com.

For further information, please contact:

Media Contact Switzerland and Europe:

Christophe Lamps

Dynamics Group

[e-mail]

[phone] Office

[phone] Mobile

Media Contact U.S.:

Marion Janic

RooneyPartners LLC

[e-mail]

[phone] Office

[phone] Mobile

CEO Office Contact:

Shauna Dillon

[e-mail]

[phone]

Investor Contact:

Mario Corso

Senior Director, Investor Relations

[e-mail]

[phone] Office

[phone] Mobile